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LONG TERM ADMINISTRATION OF PIRFENIDONE 
IMPROVES CARDIAC FUNCTION IN MDX MICE 
 
ABSTRACT 
 
Duchenne muscular dystrophy, an X-linked recessive neuromuscular disorder due to 
lack of the protein dystrophin, manifests as progressive muscle degeneration and 
cardiomyopathy with increased fibrosis. The exact mechanisms involved in fibrosis 
are unknown, but the cytokine, TGF-β, is a likely mediator.  This study tested whether 
the TGF-β antagonist, pirfenidone, could reduce cardiac fibrosis.  Eight-month-old 
mdx mice were treated for 7 months with 0.4%, 0.8%, and 1.2% of pirfenidone in 
drinking water:  untreated water was given to control mdx and C57 mice. Mice treated 
with 0.8% and 1.2% pirfendone had lowered cardiac TGF-β mRNA and improved in 
vitro cardiac contractility (P<0.05) to levels consistent with C57 mice, yet without a 
change in cardiac stiffness or fibrosis.  These results show that the TGF-β antagonist, 
pirfenidone can improve cardiac function in mdx mice, potentially providing a new 
avenue for developing cardiac therapies for patients with Duchenne muscular 
dystrophy.  
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Introduction  
Deficiency of dystrophin, due to a mutation in the dystrophin gene on the X-
chromosome, is the primary cause of Duchenne muscular dystrophy (DMD).  Boys 
with DMD often exhibit cardiomyopathy in addition to severe respiratory 
complications, with these two factors being the major contributors to mortality.  The 
incidence of symptomatic cardiomyopathy increases with age, with all patients over 
18 years having detectable cardiac disease23.  The spectrum of disease includes 
electrocardiographic changes, impaired systolic and diastolic function, and increased 
fibrosis 10,14,9.  A recent report on survival of DMD patients indicates that heart failure 
reduces the average life-expectancy significantly8, so that strategies to reduce the 
progression of cardiomyopathy and improve cardiac function are necessary to prolong 
the lifespan of many boys with DMD. 
 
Dystrophin deficiency causes repeated cycles of myocyte degeneration, consequently 
leading to increased deposition of collagenous extracellular matrix or fibrosis15,7.  In 
the heart, in addition to impairing contractility, fibrosis may interfere with impulse 
conduction and rhythm10. The precise mechanisms causing fibrosis are unknown, 
although profibrotic cytokines such as transforming growth factor-β (TGF-β) are 
likely candidates.  
 
TGF-β is a pleiotropic cytokine that plays an important role in inflammation as well 
as wound and tissue repair25.  This cytokine is expressed at high levels in the skeletal 
muscles of patients with DMD, with evidence that its level of expression is related to 
the degree of muscle fibrosis3. Similarly, in the dystrophin deficient mdx mouse, 
fibrosis in the diaphragm is associated with increased TGF-β transcript13.  Although 
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high levels of cardiac fibrosis have been reported in 17-month-old mdx mice26, there 
are no reports of TGF-β levels in dystrophic hearts, at least to our knowledge. 
 
Pirfenidone is an orally active antifibrotic drug that inhibits TGF-β–induced fibroblast 
growth and collagen synthesis in a range of tissues and disease models.  Pirfenidone 
has shown positive results in double-blind, randomized, controlled clinical trials for 
interstitial pulmonary fibrosis and has received orphan drug status in Europe and the 
United States for treatment of that condition1. Pirfenidone has also shown positive 
results in a range of experimental animal models of disease including reduced 
pulmonary fibrosis in the bleomycin hamster model16; glomerulosclerosis in the 
FGS/Kist mouse model of renal fibrosis24; collagen accumulation in postobstructive 
models of kidney fibrosis in rats28,29; and dimethylnitrosamine (DMN)-induced 
hepatic fibrosis in male Wistar King A rats31. Likewise in streptozotocin-induced 
diabetic rats, pirfenidone reversed cardiac and renal fibrosis, without normalizing 
cardiac contractility or renal function19.  In this animal model, pirfenidone decreased 
fibrosis despite not increasing the rate of pressure development, but the underlying 
impairment of contractility in this disease state is not solely related to the increase in 
fibrosis but also to marked changes in calcium handling33.  In the mdx mouse the basis 
for impaired cardiac contractility has not been clearly delineated and it is therefore 
possible that a decrease in fibrosis may improve contractility.  
 
As the antifibrotic action of pirfenidone has been demonstrated in several animal 
models of fibrosis in different organs including heart, lung, kidney, and liver, we 
tested whether administration of pirfenidone would elicit an antifibrotic action on 
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cardiac muscle and improve functional responses in mdx mice, a model that displays 
extensive cardiac fibrosis later in life.   
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Materials and Methods 
 
Treatment Protocol 
Male C57BL10ScSn mice (control strain) (C57) and C57BL10ScSn mdx mice (mdx) 
were housed at our institutional animal facility.  Eight-month-old mdx mice were 
randomized into four groups, with nine mice per group.  Three groups of mdx mice 
were treated with pirfenidone (Intermune, Brisbane, CA) in their drinking water at the 
following concentrations: 0.4, 0.8 and 1.2 g/100 ml.  A further group of mdx and C57 
mice received untreated drinking water and were designated mdx and C57 controls.  
The rate of water consumption was measured and did not differ between the treated 
and untreated mice.  This treatment regime allowed assessment of the drug-induced 
benefit relative to the untreated mdx and C57 mice.  All animals were given free 
access to feed.   
 
Preliminary experiments showed that hearts from 8-to 9-month-old mdx mice did not 
show an elevation in ventricular hydroxyproline content, whereas hearts from 15-
month-old mdx mice showed both elevated ventricular hydroxyproline and impaired 
ventricular contractility.  Therefore all mice were treated for a total of 7 months 
allowing a final age of 15 months.  All experimental protocols were conducted with 
the approval of our institutional Animal Ethics Committee, under the guidelines of the 
National Health and Medical Research Council of Australia. 
 
Langendorff Experiments 
Mice at 15 months of age were weighed and anaesthetized with sodium pentobarbital 
(Nembutal, Boehringer Ingelheim, Artarmon, NSW, Australia) at 70 mg/kg 
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administered intraperitoneally.  A thoracotomy was performed and hearts were 
rapidly excised into modified Krebs-Henseleit buffer containing (mM): NaCl, 119; 
NaHCO3, 22; KCl, 4.7; KH2PO4, 1.2; CaCl2, 2.5; MgSO4, 1.2; glucose, 11; Na-
pyruvate, 1 and EDTA, 0.5  containing 10 mM 2,3-butanedione monoxime 
(temperature 21°C). The aorta was cannulated via the dorsal root and perfused at a 
pressure of 80 mmHg with Krebs-Henseleit perfusion buffer maintained at 37°C and 
bubbled with carbogen (95%O2-5%CO2) to ensure a pH of 7.4.   
 
A small polyethylene apical drain was used to vent the left ventricle preventing an 
accumulation of fluid in this chamber via Thesbian veins.  The left atrium was excised 
and a fluid-filled balloon constructed from polyvinyl chloride plastic film was 
inserted into the left ventricle via the mitral valve for the measurement of left 
ventricular function. The left ventricular function was recorded via a MLT844 
physiological pressure transducer (ADInstruments, Castle Hill, NSW, Australia) 
linked to a PowerLab recording system (ADInstruments). Coronary flow was 
regulated via a ML175 STH Pump Controller (ADInstruments). 
 
Hearts with a coronary flow greater than 5 ml/min, indicating an aortic tear or aortic 
valve rupture, were to be excluded from the experimental analysis; only one mouse 
reached this exclusion criteria.  Data were recorded using Chart 4.1.1 software 
(ADInstruments) to calculate end-systolic pressure (ESP) and end-diastolic pressure 
(EDP), developed pressure and relaxation over time (±dP/dt), and heart rate.  Fluid 
temperature was measured via a thermometer at the entry of the aortic cannula, and 
temperatures were maintained at 37.3°C.   
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Hearts were paced at 420 bpm via a Grass S48 stimulator (West Warwick, RI) and a 
silver wire embedded into the left ventricle and grounded using an electrode attached 
to the cannula.  The balloon was inflated to an EDP between 0 and 5 mmHg and the 
heart was then equilibrated for 10 minutes at this pressure.  Following this 
equilibration period, the EDP was measured for 30 seconds at each of the following 
increments:  0, 5, 10, 15, 20 and 30 mmHg.  Myocardial stiffness was defined by the 
stiffness constant (κ, dimensionless), that is, the slope of the linear relationship 
between the tangent elastic modulus (E, dyne/cm2) and stress (σ, dyne/cm2) as 
described in detail elsewhere21. 
 
At cessation of the in vitro experiments, the right atrium, right ventricle, and left 
ventricle plus septum were separated and weighed.  The left ventricle plus septum was 
bisected transversely with the superior portion stored for histology.  Half of the 
remainder was snap frozen in liquid nitrogen and stored at -80°C for subsequent 
hydroxyproline assays and the other half was stored in RNAlater (Ambion, Austin, 
TX) for subsequent determination of TGF-β mRNA levels. 
 
Hydroxyproline Measurements 
Hydroxyproline (HP) assays were used as a measure of collagen content.  The frozen 
left ventricular section was weighed and placed in a sealed tube containing 6 M HCl.  
The following protocol has been described previously in detail30.  Briefly, the tissue 
was hydrolyzed overnight at 110°C before being dried using low heat (50°C) and 
filtered air under pressure. The dried sample was reconstituted with distilled water 
and Chloramine T reagent was added to each sample.  The oxidation step was then 
allowed to progress for 20 minutes before Ehrlich’s reagent was added.  The samples 
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were subsequently incubated at 60°C in a shaking water bath for 20 minutes to allow 
the chromophore to develop.  Values are expressed as µg HP/mg of wet tissue weight.  
Absorbance was read at 550 nm and HP content was calculated from a standard curve.  
 
Histology 
The superior ventricular sections were fixed in Telly’s fixative (70% ethanol, 37% 
formaldehyde and glacial acetic acid) for 3 days, modified Bouin’s solution (saturated 
picric acid, 37% formaldehyde and glacial acetic acid) for 1 day and 70% ethanol 
before the muscles were embedded in paraffin wax.  Sections of 10-µm thickness 
were cut and placed on Polysine glass slides and stained using the collagen selective 
stain, 0.1% wt/vol picrosirius red solution (Sirius Red F3B, Chroma Dyes, in 
saturated picric acid).  Slides were left in 0.2% phosphomolybdic acid for 5 minutes, 
then washed, stained in picrosirius red for 90 minutes and then placed in 1 mM HCl 
for 2 minutes.  Slides were then placed in 70% ethanol for 30 seconds and 
coverslipped using Depex.   
 
Stained muscle sections were viewed blinded to the strain and treatment of the mouse 
using a Nikon Eclipse E600 epifluorescence microscope and 200X magnification. 
Images were captured with a cooled charge-coupled device (CCD) digital camera 
(Micropublisher 5.0, QImaging, Burnaby, Canada).  Picrosirius red-stained cardiac 
sections were viewed under polarized light to determine the ratio of type I and type III 
collagen17.  The automated red:green color separation and phase analysis module 
within AnalySIS software (Soft Imaging System, GmbH, Münster, Germany) were 
used to calculate the area of each collagen subtype within each field of view and to 
remove operator bias.  To determine an average percentage of collagen in each left 
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ventricle, the total collagen of the type I and type III was calculated from two 
endocardial and three epicardial regions of the left ventricle.   
 
TGF-β mRNA Measurements 
RNAlater treated frozen samples were cut into 6-µm sections and total RNA 
extracted with an RNAqueous Kit (Ambion).  All samples were DNase treated with 
Turbo DNA-free (Ambion) prior to reverse transcriptase-polymerase chain reaction 
(RT-PCR) and screened for genomic DNA. RNA was quantified using Quant-it 
Ribogreen RNA Assay Kit (Molecular Probes; Invitrogen, Eugene, OR).  Relative 
RT-PCR was carried out with 100 pg of total RNA as the starting material for 26 
cycles of amplification in the Titan One-Tube RT-PCR system (Roche Molecular 
Biochemicals, Mannheim, Germany).  TGF-β was amplified with the following 
primers:  forward, TGF-β 1446F 5’-TGAGTGGCTGTCTTTTGACG-3’; reverse, 
TGF-β 1738R 5’-TCTCTGTGGAGCTGAAGCAA-3’.  β-actin was co-amplified as 
an internal control using the following primers:  forward, β-actin F561 5’-
CACACTGTGCCCATCTACGA-3’; reverse, β-actin R688 5’-
GTGGTGGTGAAGCTGTAG-3’.   
 
To determine specificity, all sequences were compared with Genbank Blast 
(www.ncbi.nlm.nih.gov).  TGF-β and β-actin primers were used at a concentration of 
10 µM and 20 µM, respectively.  Optimal magnesium chloride concentration was 1.0 
mM, with all other reaction components added as per manufacturer’s instructions.  
Multiplex reactions were carried out on a ThermoHybaid PCR Express (Integrated 
Sciences, Sydney, NSW, Australia).  A first cycle of 48oC for 30 minutes was 
undertaken for cDNA synthesis.  An initial denaturation step of 94oC for 2 minutes 
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was performed, followed by a touch-down PCR protocol as described below: 30 
seconds at 94oC, 1 minute at 62oC, 2 minutes at 72oC for 2 cycles; 30 seconds at 94oC, 
1 minute at 60oC and 2 minutes at 72oC for 2 cycles; 30 seconds at 94oC, 1 minute at 
58oC and 2 minutes at 72oC for 2 cycles; 30 seconds at 94oC, 1 minute at 56oC and 2 
minutes at 72oC for 20 cycles.  A final extension was performed at 72oC for 5 
minutes.  Cycling parameters were optimized to ensure exponential phase 
amplification of TGF-β and β-actin.  PCR products were run on a 2% agarose gel in 
Tris Acetate EDTA buffer and visualised with ethidium bromide.  A PCR DNA 
ladder (New England Biolabs, Ipswich, MA) was run on each gel to confirm the 
expected molecular weight of the amplification product.  Results were analysed using 
Scion Image Software beta 4.0.2 (www.scioncorp.com) and TGF-β product 
normalized by comparison to the β -actin internal control product.   
 
Statistical Analysis 
Data are presented as mean ± SEM, and comparisons were made using ANOVA.  
Differences between groups were determined post hoc using Tukeys HSD test if 
variances were shown to be equal or Games-Howell post hoc test if variance was 
unequal.  A value of P<0.05 was considered statistically significant.   
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Results 
Cardiac Structure and Function 
Mdx mice had impaired cardiac function relative to age and-sex-matched C57 mice, 
as evidenced by a reduction of 26% in left ventricular developed pressure (P<0.001), 
29% in +dP/dt (P<0.01) and 21% in –dP/dt (P<0.01; Fig. 1). In contrast, mdx mice 
treated with 0.8% and 1.2% pirfenidone showed a significantly improved cardiac 
contractility with developed pressure increased in mdx mice to a level commensurate 
with that measured in hearts from C57 mice. Similarly, +dP/dt was improved in mdx 
mice treated with 0.8% pirfenidone (P<0.01), and was close to significance in mice 
treated with 0.4% (P<0.07) and 1.2% (P<0.08).  Associated with this -dP/dt was also 
improved with 0.8% pirfenidone (P<0.06), with this reaching significance in 1.2% 
pirfenidone (P<0.05) compared to untreated mdx mice, resulting in values similar to 
those measured in hearts from C57 mice.  There were no significant differences in 
coronary flow or diastolic stiffness between the untreated mdx and C57 mice or 
between hearts from untreated and pirfenidone treated mdx mice (Table 1). 
 
To determine whether changes in contractility were related to reduced fibrosis, 
cardiac collagen content was measured.  Hydroxyproline content was higher in the 
left ventricles of untreated mdx mice than C57 control mice (P<0.01) but pirfenidone 
did not reduce hydroxyproline content (Fig. 2). These findings were reinforced by 
analysis of picrosirius red-stained left ventricular sections, which showed that total 
collagen was increased in mdx mice (P<0.05) but unaltered by pirfenidone treatment 
(Fig. 3). The ratio of type I:III collagen was not different between treated and 
untreated mdx mice, nor was a ratio difference evident between mdx and C57 mice 
(Table 1).   
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TGF-β mRNA expression 
 
To confirm that pirfenidone lowered TGF-β mRNA expression, RT-PCR experiments 
were undertaken. The quantity of TGF-β mRNA was not different between mdx and 
C57 mice.  Pirfenidone treatment at concentrations of 0.8 and 1.2% decreased the 
TGF-β mRNA levels significantly (P<0.01) compared to both the C57 and untreated 
mdx mice. (Fig. 4) 
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Discussion 
 
The aged mdx mouse exhibits several cardiomyopathic features similar to those 
observed in DMD cardiomyopathy.  We assessed ventricular function in mdx mice 
older than 12 months of age and found evidence of reduced ventricular contractility, 
rate of pressure development, and rate of relaxation in the mdx mouse heart. These 
features correspond to the cardiac features in boys with DMD where there is also 
increased fibrosis with reduced systolic and diastolic function4. The mdx mouse 
ventricles also exhibit significantly elevated collagen content evident by picrosirius 
red staining, as reported previously,26 with no change evident in collagen I:III ratio.  
Using hydroxyproline assays, this increase in collagen has been further verified.  
Interestingly, despite the increased cardiac collagen, there was no difference in 
diastolic stiffness. This was unexpected although a similar finding was reported in 
younger mdx mice32. Because different collagen subtypes contribute to stiffness, we 
assessed the ratio of subtype I and III, but found no difference between mdx and C57 
mice. The lack of increased stiffness in older mdx mice suggests low levels of 
crosslinking or other compensatory changes in the mdx mouse to allay the effects of 
the increased collagen5,2.  
 
We investigated the effect of pirfenidone in mdx mice and the long-term efficacy 
study with pirfenidone in animals.  The results show that 0.8% and 1.2% pirfenidone 
reduced TGF-β mRNA levels associated with a marked improvement in cardiac 
function, yet without a reduction of ventricular collagen content.  Evidence of 
improved cardiac function included increased ventricular developed pressure, +dP/dt 
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and -dP/dt. Importantly, these functional parameters improved to values that were not 
significantly different to values measured in C57 mice.  
 
While treatment with pirfenidone has reproducibly shown antifibrotic effects in a 
range of acutely induced fibrosis in tissues including lungs, liver, kidneys and heart, 
no antifibrotic effect was evident in this study.  Many animal studies investigating the 
action of pirfenidone have utilized rats or hamsters in their research, but because mice 
have a higher relative metabolic rate, a range of doses was tested.  Therefore, in our 
study mice received a range of doses from 0.4% to 1.2% in water (equating to 
approximately 0.4-1.2 g/kg) in contrast to previous studies in rats and hamsters that 
utilized lower doses of  pirfenidone at a dose of 0.4 to 0.5% in food (equating to 
approximately 0.3-0.7 g/kg). Therefore, the lack of anti-fibrotic effects in this study 
are unlikely to be due to an insufficient dosage, particularly as 0.8% and 1.2% 
pirfenidone both reduced TGF-β mRNA even though no concurrent reduction 
occurred in fibrosis.  
 
It can be hypothesized that the lack of observed antifibrotic effect with pirfenidone 
treatment is due to either: (1) fibrosis in mdx mouse hearts increasing with age due to 
impairment of collagen degradation in addition to increased collagen synthesis; or (2) 
advanced establishment of profibrotic pathways in the mdx mouse hearts by 8 months 
of age, which was when pirfenidone treatment commenced.  
 
In support of the first possibility, recent data obtained from diaphragms of mdx mice 
shows extensive and progressive development of fibrosis from early in life with 
increased procollagen 1 mRNA evident from 6 weeks of age.  However, by 12 weeks 
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of age, no difference in procollagen 1 mRNA was evident between mdx and C57 
mouse diaphragms, suggesting reduced degradation rather than increased fibrosis is 
the basis of increased collagen content13. This, in turn, would reduce the likelihood of 
antifibrotic benefits of pirfenidone, especially in mice at 15 months of age. 
 
In support of the second possibility, the mdx mouse undergoes an acute inflammatory 
response early in life with increased expression of cytokines including TNF-α and 
TGF-β, which may lay the foundation for pathways leading to increased fibrosis. For 
example, TGF-β expression is elevated at 6 and 9 weeks of age, but not at 12 weeks13, 
suggesting profibrotic pathways are initiated early.  This would also explain why 
TGF-β mRNA levels were not different in the hearts of the 15-month-old mdx mice 
compared to the C57 mice. Treating mice older than 6 to 9 weeks with pirfenidone, 
which acts to inhibit TGF-β expression, is thus unlikely to be effective.  Further 
support for the need to intervene early in the inflammatory process is that treatment of 
hamsters with pirfenidone for 3 days before amiodarone-induction of pulmonary 
fibrosis prevented subsequent fibrosis when measured at its peak, 21 days later.  In 
contrast, delaying pirfenidone treatment until 7 days post-amiodarone treatment did 
not protect against fibrosis developing.  This lack of antifibrotic effect occurred 
despite the capacity of pirfenidone to reduce TGF-β mRNA, although to a lesser 
extent than the reduction that was measured with pirfenidone administration prior to 
amiodarone-induction of pulmonary fibrosis6.  
 
The current study shows that long-term treatment causes a clear improvement in 
cardiac function, in contrast to previous studies.  Acute rat models of cardiovascular 
diseases, deoxycorticosterone-acetate (DOCA)-salt and streptozotocin (STZ)-induced 
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diabetes did not show improved cardiac contractility after pirfenidone treatment for 2 
weeks at doses that were effective at preventing increased fibrosis and diastolic 
stiffness19,20.  These differences may be due to species differences or duration of 
treatment. 
 
Recent studies have shown that pirfenidone also modifies numerous other cytokines, 
including inhibition of TNF-α, interferon-γ, and interleukin-6, while enhancing 
synthesis of the anti-inflammatory cytokine interleukin-10 in mouse and rat models of 
endotoxic shock22,18.  Pirfenidone may also scavenge reactive oxygen species12 which 
are elevated and cause detrimental effects in mdx mouse tissues27.  Pirfenidone’s 
capacity to scavenge reactive oxygen species and lower levels of H2O2, OH- and O2- 
may be a basis of improved cardiac function. Furthermore, since it is increasingly 
recognized that cardiomyopathy is a complex neurohumoral disorder involving many 
inflammatory cytokines, it is unlikely that inhibition of a single cytokine will be 
useful in the treatment of cardiomyopathy11.  Whether pirfenidone acts solely through 
inhibition of TGF-β or through inhibition of a range of inflammatory cytokines, 
remains to be resolved.   
 
In conclusion, long-term treatment with pirfenidone improves cardiac function in mdx 
mice, but does not prevent fibrosis when treatment is commenced later in the lifespan.  
The higher pirfenidone doses (0.8% and 1.2%) decreased TGF-β RNA expression and 
these same doses caused an increase in cardiac function. It appears that the 
administration of pirfenidone at 0.8% is the optimum dose for mdx mice to produce 
the most significant cardiac function improvement.  Further studies should investigate 
the actions of pirfenidone during the acute inflammatory stage of the disease to 
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determine if earlier administration will inhibit upregulation of inflammatory or 
profibrotic cytokines to improve both function and prevent fibrosis, both of which 
would be beneficial in treatment of DMD.   
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Abbreviations 
 
DMD,  Duchenne Muscular Dystrophy 
+dP/dt, rate of pressure development 
-dP/dt,  rate of relaxation 
EDP,  end-diastolic pressure  
ESP,  end-systolic pressure  
HP,  hydroxyproline 
RT-PCR, reverse transcriptase-polymerase chain reaction 
TGF-β, Transforming growth factor-beta 
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Figure Legends 
 
Figure 1: Cardiac function from control mdx and C57 mice and the pirfenidone-
treated mdx mice. Left ventricular developed pressure (A); Rate of pressure 
development (+dP/dt) (B); and rate of relaxation (-dP/dt) (C). Untreated mdx had a 
lower function relative to C57 mice whereas 0.8% and 1.2% pirfenidone treatment 
improved function to levels similar to those measured in hearts from C57 mice.  
++P<0.01, +++ P<0.001 (C57 vs. mdx control mice) *P<0.05, **P<0.01 (pirfenidone 
treated mdx vs. control mdx mice).  
 
Figure 2: Left ventricular hydroxyproline content from control mdx and C57 mice and 
pirfenidone-treated mdx mice. Control and treated mdx mice had significantly higher 
hydroxyproline content than C57 mice.  +P<0.05; C57 vs. mdx control.   
 
Figure 3: Left ventricular sections of control mdx and C57 and pirfenidone treated 
mdx mice. Total collagen was higher in untreated mdx mice and was unaltered by 
pirfenidone treatment. Viewed under polarized light, magnification: X200. Areas 
stained red/yellow indicate presence of collagen I and areas stained green indicate 
presence of collagen III.  The rectangle in the C57 photomicrograph is shown 
enlarged in the image to the right.  The arrow shows green birefringence. 
 
Figure 4: Relative RT-PCR quantification of TGF-β normalized to β-actin expression.  
Relative RT-PCR gel of TGF-β (293 bp) and β-actin (127 bp) (A).  Quantified TGF-β 
expression relative to β-actin (B).  Pirfenidone at doses of 0.8% and 1.2% inhibited 
 25
TGF-β mRNA expression. significantly compared to both the C57 and untreated mdx 
mice.  ++P<0.01  
 
Table 1:  Diastolic stiffness (κ), normalized coronary flow (ml/mg heart weight) and 
ratio of collagen I:III values for control and pirfenidone treated mice.  No significant 
differences were evident between either strains or treatment groups. 
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  mdx:  Pirfenidone treatment 
  
C57 
 
0 
 
0.4% 
 
0.8% 
 
1.2% 
 
Diastolic 
Stiffness 
(κ) 
 
32.56±1.29 29.92±2.4 31.34±2.69 33.11±2.13 29.77±2.44 
Coronary 
Flow 
(ml/mg ht 
wt) 
 
0.024±0.001 0.024±0.001 0.025±0.002 0.027±0.001 0.024±0.01 
Ratio 
Collagen 
I:III 
2.15±0.14 2.06±0.045 2.30±0.09 2.20±0.1 2.2±0.04 
 
Table 1 
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